Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Oklo Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.67 (market cap $39.89B), while Oklo Inc trades at $46.41 (market cap $8.50B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.7× Oklo Inc's market cap. Which is the better fit depends on your goals.
| ALNY | OKLO | |
|---|---|---|
Market Cap | $39.89B | $8.50B |
Sector | Health | Technology |
52-Week High | $491.22 | $174.14 |
52-Week Low | $278.09 | $45.58 |
Enterprise Value | $38.15B | $6.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
OKLO trades at $48.85, down 0.85% on the day, reflecting ongoing volatility as the stock remains 70% below its 52-week high. Technical indicators show a bearish trend with support at $45, while fundamentals reveal significant losses with a net income of -$105.66M in 2025. Recent news highlights progress with DOE safety approvals for its Groves reactor, but investor sentiment is mixed amid substantial cash burn and equity dilution from financing activities.
The outlook hinges on successful reactor deployment and commercialization, with analyst consensus pointing to 96% upside potential. Key risks include execution delays, regulatory hurdles, and persistent negative cash flow from operations. Long-term growth depends on converting nuclear technology advancements into revenue, making it a high-risk, high-reward opportunity for speculative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
